Adage Capital Partners
ESPR

Adage Capital Partners’s Esperion Therapeutics ESPR Stock Holding History

Adage Capital Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-86,484
Closed -$2.73M – 759
2020
Q1 		$2.73M Buy
+86,484
New +$4.56M 0.01% 636

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Adage Capital Partners's ESPR Position: Q2 2020 in Review

Adage Capital Partners sold out of Esperion Therapeutics (ESPR) in Q2 2020, closing a stake of 86,484 shares — an estimated $2.73M sold.

Adage Capital Partners first reported a position in ESPR in Q1 2020 and held it in 1 quarter. The position peaked at $2.73M in Q1 2020. 182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Adage Capital Partners reported no remaining Esperion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Adage Capital Partners sold 86,484 Esperion Therapeutics shares in Q2 2020, an estimated $2.73M.
  • Adage Capital Partners first reported a position in Esperion Therapeutics in Q1 2020 and held it in 1 quarter.
  • Adage Capital Partners's Esperion Therapeutics position peaked at $2.73M in Q1 2020.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.